The QuantifyHER study, sponsored by the Abramson Cancer Center at Penn Medicine, aims to evaluate a quantitative HER2 assay for its ability to predict treatment response in patients with HER2-low metastatic breast cancer receiving T-DXd (Enhertu). This study targets a niche yet significant segment of the breast cancer market, particularly focusing on patients with HER2 IHC 1+ expression. The findings could enhance the precision of HER2-targeted therapies, potentially leading to improved patient outcomes and positioning the sponsor favorably in the competitive landscape of breast cancer therapeutics. The study's collaboration with Danaher Inc. may also indicate a strategic partnership for diagnostic development, which could further strengthen market positioning.